Telehealth company Hims & Hers saw its stock fall 15.7% in premarket trading after reporting a first-quarter net loss of $92 million, nearly double last year's $50 million loss. Revenue rose 4% to $608 million, but average monthly revenue per subscriber declined. The company forecast second-quarter revenue between $680 million and $700 million and full-year revenue up to $3 billion, with adjusted EBITDA expected to reach $55 million in Q2 and $350 million for the year. Analysts noted the outlook was mixed and highlighted a transition as Hims reduces reliance on compounded GLP-1 weight loss drugs following a deal with Novo Nordisk to sell branded Wegovy on its platform.
Hims & Hers Health has been upgraded to a buy rating due to stronger-than-expected sales of its branded GLP-1 drug Wegovy, which shipped 125,000 units in six weeks. Management now expects over 100,000 monthly new weight-loss subscribers, restoring co...
Hims & Hers Health increased its full-year 2026 revenue guidance to $2.8-$3.0 billion despite reporting a quarterly EPS loss impacted by restructuring charges. The company showed strong subscriber growth nearing 2.6 million and high engagement with 9...
Shares of Hims & Hers Health dropped after JPMorgan lowered its price target from $35 to $33 following a mixed first-quarter report and a strategic shift from compounded to branded GLP-1 medications. Despite the cut, JPMorgan maintained an Overweight...
Hims & Hers shares fell about 14% in pre-market trading following a disappointing Q1 report, attributed to timing of the Novo Nordisk deal and tough year-over-year comparisons. Despite the initial drop, analysts see the Q2 guidance beat and raised fu...
Hims & Hers Health reported Q1 results missing expectations with revenue up only 4% year-over-year and US revenue down 8%. Earnings per share fell to -$0.40 from $0.20 last year, while monthly revenue per subscriber declined 6% to $80 despite a 9% in...
